+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites



Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites



Acta Neuropsychiatrica 19(1): 45-52



The tryptophan metabolite kynurenic acid (KYNA) is an endogenous glutamate/nicotinic receptor antagonist. Previous studies have shown that the concentration of the compound is increased in cerebrospinal fluid (CSF) of patients with schizophrenia. Furthermore, it has been found that the CSF concentration of KYNA is positively correlated to CSF concentrations of the monoamine metabolites homovanillic acid (HVA) and 5-hydroxy indoleacetic acid (5-HIAA) in healthy control subjects. To study the correlations between KYNA and the monoamine metabolites HVA, 5-HIAA and 4-hydroxy-3-methoxyphenylglycol (HMPG) in CSF of male patients (n= 53, ranging from 20 to 48 years of age) with verified schizophrenia. CSF was obtained by lumbar puncture, and KYNA analysis was performed with an isocratic reversed-phase high-performance liquid chromatography system connected to a fluorescence detector. HVA, 5-HIAA and HMPG concentrations were measured by mass fragmentography with deuterium-labelled internal standards. Positive intercorrelations were found between CSF KYNA, HVA and 5-HIAA, while CSF content of HMPG did not correlate to KYNA or any of the monoamine metabolites in CSF. The results of this study suggest that increased KYNA formation is associated with an increased dopamine and serotonin turnover in male patients with schizophrenia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057374176

Download citation: RISBibTeXText

PMID: 26952797

DOI: 10.1111/j.1601-5215.2006.00170.x


Related references

Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. Journal of Psychiatric Research 41(1-2): 144-151, 2006

Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research 80(2-3): 315-322, 2005

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 313(1-2): 96-98, 2001

Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia. Clinical Pharmacology & Therapeutics 36(1): 33-39, 1984

Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology 22(1): 62-67, 1972

Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. American Journal of Psychiatry 154(1): 69-74, 1997

Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: studies in psychiatric patients. Psychopharmacology 62(1): 17-22, 1979

Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer's disease). Acta Psychiatrica Scandinavica 49(3): 257-263, 1973

Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. European Neurology 9(6): 349-362, 1973

Acid Monoamine Metabolites in the Cerebrospinal Fluid of Parkinsonian Patients Treated with Levodopa alone or Combined with a Decarboxylase Inhibitor. European Neurology 9(6): 349-362, 1973

Effect of ischemia on monoamine metabolism. Brain monoamine metabolites in cerebrospinal fluid of patients with recent cerebral infarction. NeuropatologiaPolska20(1-2):97, 1982

Relapse in violent crime in relation to cerebrospinal fluid monoamine metabolites (5-HIAA, HVA and HMPG) in male forensic psychiatric patients convicted of murder: a 16-year follow-up. Acta Psychiatrica Scandinavica. Supplementum 2002(412): 71-74, 2002

Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. Journal of Psychiatric Research 44(12): 754-759, 2010

Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Archives of General Psychiatry 47(7): 641-648, 1990

Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients. Biological Psychiatry 56(6): 418-426, 2004